01.09.2026 – 12:17

BR Bayerischer Rundfunk

Happy Birthday, "schlachthof"! "Kabarett-Institution" des BR feiert 30. Geburtstag

Stars und Wegbegleiter gratulieren - Jubiläumssendung am 17. September

Bild-Infos Download

München (ots)

Der BR-Kabarett-Klassiker "schlachthof" feiert 30. Geburtstag! Gefeiert wird mit einer prominent besetzten Spezialausgabe am 17. September, doch schon jetzt gratulieren zahlreiche Kolleginnen und Kollegen von Eva Karl Faltermeier über Wolfgang Krebs und Luise Kinseher bis Christian Ehring (nachzulesen im Pressedossier). Als "klug", "unbequem" und "mit Herz" wird die Sendung immer wieder beschrieben. Und als ein Format, das Menschen verbinden will, statt zu trennen.

Auch Björn Wilhelm, BR-Programmdirektor Kultur, würdigt die Sendung als "Kabarett-Institution" im BR Fernsehen: "Der 30. Geburtstag einer Sendung ist im schnelllebigen Fernsehgeschäft wirklich etwas ganz Besonderes und zeigt, wie wichtig die Arbeit der Macherinnen und Macher ist. Was der großartige Ottfried Fischer mit 'Ottis Schlachthof' begonnen hat, führen Michael Altinger und Christian Springer seit 2013 hervorragend weiter - mit renommierten Gästen, scharfen Pointen und immer auch politischen und aktuellen Bezügen. Sie haben so eine echte Kabarett-Institution im BR Fernsehen geschaffen. Danke und herzlichen Glückwunsch an das gesamte Team für immer sprachmächtige Satire, für 30 Jahre Humor und Relevanz!"

Hochkarätig besetzte Geburtstagsfeier

Zur Jubiläumssendung im September (Ausstrahlung am Donnerstag, 17.9.) haben sich Michael Altinger und Christian Springer das Who is Who der bayerischen Kabarettszene ins traditionsreiche Münchner Wirtshaus im Schlachthof eingeladen: Zugesagt haben bereits Luise Kinseher, Günter Grünwald, Alfred Dorfer, Constanze Lindner, Maxi Schafroth und Berni Wagner. Martin Frank unterstützt als "Archivar", und "Zwischenruferin" Teresa Reichl ist auch mit von der Partie. Der Stammtisch aus der Ursprungssendung ist mittlerweile einem moderneren Bar-Tresen gewichen, dafür gibt es diesmal eine Art "Neben-Stammtisch" im Publikum: An ihm sitzt schlachthof-Urgestein Ottfried "Otti" Fischer, der die Sendung einst ins Leben rief, mit einem Teil der Gäste.

Von "Ottis Schlachthof" zum "schlachthof"

Alles begann mit einer Idee: ein zwangloser Stammtisch-Talk, moderiert von Kabarettlegende Ottfried Fischer. Um das Thema "Fleisch essen und andere Perversionen" ging es in einer Testfolge im Dezember 1995, bevor die Sendung dann im März 1996 in Serie ging - und vom Publikumserfolg zum Dauerbrenner wurde. Anfangs talkte Otti Fischer noch mit Laien, es ging ernster zu und es wurde auch heftig gestritten. Doch schon in der ersten Regelfolge kamen dann Vertreter aus Kleinkunst und Kabarett (damals Jochen Busse und Andreas Giebel) dazu, die den Gesprächspart mit Auftritten ergänzten - die Geburtsstunde des "schlachthof"-Konzepts, wie die Zuschauer es bis heute kennen und lieben.

Mehr als 16 Jahre prägte Otti Fischer die Sendung, bevor im März 2013 Michael Altinger und Christian Springer übernahmen, den Klassiker in die Zukunft führten und ihm einen neuen Anstrich und ihre ganz eigene Note gaben. Aus dem Programm im BR Fernsehen ist die Sendung heute nicht mehr wegzudenken - der "schlachthof" holt regelmäßig bis zu 500.000 Zuschauerinnen und Zuschauer und hat eine treue Fangemeinde.

Weitere Infos im Pressedossier

Fotos unter www.br-foto.de bzw. E-Mail an bildmanagement@br.de

Pressekontakt:

BR-Pressestelle

Wibke Heise

E-Mail: wibke.heise@br.de

Tel. +49 (0)89 5900-10554

Von der Kuhlen Kommunikation

Claudia Pantke

E-Mail: c.pantke@vonderkuhlen.de

Tel. +49 (0)151 50058146

www.br.de/presse

Original-Content von: BR Bayerischer Rundfunk, übermittelt durch news aktuell

Garmin launches innovative SmartDrive autopilot for sailboats and catamarans

NEWS PROVIDED BY

Garmin International, Inc.

Sep 01, 2026, 07:02 ET

SHARE THIS ARTICLE

First sailboat autopilot to use brushless linear actuator with built-in ECU for superior performance, reliability and simplified installation

OLATHE, Kan., Sept. 1, 2026 /PRNewswire/ -- Garmin (NYSE: GRMN), the world's largest1 and most innovative marine electronics manufacturer, today announced SmartDrive™, a ground-breaking autopilot system that leverages a brushless linear actuator, built-in ECU and a rudder feedback sensor for improved durability and long-term reliability. Designed for sailboats and catamarans up to 45 feet (maximum displacement of 33,000 pounds), the Reactor 40 Corepack with SmartDrive provides top-tier autopilot performance with up to 1,050 pounds of maximum thrust, helping maintain steady rudder control to help captains stay on course.

First sailboat autopilot to use brushless linear actuator with built-in ECU for superior performance, reliability and simplified installation.

"Whether out for a day trip or a longer voyage, sailors need dependable technology. SmartDrive was designed from the ground up to deliver precise steering, long-term durability, a quiet ride and reliable performance in demanding offshore conditions, giving sailors confidence wherever their journey takes them."

—Susan Lyman, Garmin Vice President of Global Consumer Sales & Marketing

Streamlined installation and seamless compatibility

The innovative SmartDrive operates with fewer cables and external components, allowing for a streamlined installation. With a form factor like other linear actuators, SmartDrive is designed to simplify retrofit installations and serve as an easy direct replacement. It also seamlessly integrates with compatible Garmin MFDs via the NMEA® 2000 network.

Bundling options

Sailors have the option of purchasing the SmartDrive autopilot actuator on its own, or as part of an exciting bundle with a complete Corepack that can elevate the sailing experience, including improved wind hold performance, more accurate tack and gybe with adjustable speeds and auto response, and easy calibration using the dockside wizard. The Reactor 40 Sail Corepack with SmartDrive bundle includes a CCU with built-in solid-state 9-axis AHRS and a GHC™ 50 autopilot display, which allows users to control the autopilot from a 5-inch touchscreen from different locations on board.

For more ways to control the autopilot system, the Reactor 40 Corepack with SmartDrive is compatible with several Garmin devices, including the Reactor 40 autopilot wireless remote, the APK™ 10 autopilot keypad and select quatix® marine smartwatches2.

The SmartDrive actuator is available as a standalone purchase for a suggested retail price of $3,499.99 or as part of a Reactor 40 Sail Corepack bundle that starts at $4,499.99. To learn more, visit garmin.com/marine.

Engineered on the inside for life on the outside, Garmin products have revolutionized life for anglers, sailors, mariners and boat enthusiasts everywhere. Committed to developing the most innovative, highest quality, and easiest to use marine electronics the industry has ever known, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. For the 11th consecutive year, Garmin was named the Manufacturer of the Year by the National Marine Electronics Association (NMEA). Visit the Garmin Newsroom, email our media team, connect with @garminmarine on social, or follow our blog.  

1Based on 2025 sales.

2Requires a compatible Garmin chartplotter or GHC 50 autopilot instrument.

About Garmin: Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan, and the United Kingdom. Garmin and quatix are registered trademarks, and SmartDrive, Reactor, GHC and APK are trademarks of Garmin Ltd., or its subsidiaries.

All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.

Notice on Forward-Looking Statements:

This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 27, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). Copies of such Form 10-K are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

MEDIA CONTACTS:

Mike Cummings and Carly Hysell

913-397-8200

media.relations@garmin.com

SOURCE Garmin International, Inc.

21%

more press release views with 

Request a Demo

94% of U.S. Adults Concerned About the Frequency of Food Recalls, New GS1 US Survey Shows

NEWS PROVIDED BY

GS1 US

Sep 01, 2026, 07:00 ET

SHARE THIS ARTICLE

Consumers Remain Confident Recalls Protect Public Health, But Growing Caution Underscores the Need for Faster, More Precise Traceability

EWING, N.J., Sept. 1, 2026 /PRNewswire/ -- Ninety-four percent of U.S. adults say they are concerned about the frequency of food recalls, up slightly from 93% in 2025, according to a new consumer survey commissioned by GS1 US. At the same time, fewer people believe food recalls are effective in protecting public health and safety, (80% compared to 85% in 2025), underscoring consumers' diminishing trust in the U.S. food supply.

The survey shows that consumers are increasingly taking broader precautions following food safety incidents:

67% have avoided an entire food product category following a recall, up from 60% in 2025.

66% are hesitant to purchase the same product or brand again, up from 59% last year.

59% have discarded recalled food even when their state or region was not affected, compared with 57% in 2025. Women are especially likely to pull back, with 71% saying they have avoided a whole category, compared with 63% of men.

While only 9% of consumers report that they would never purchase the recalled brand again, those who would consider repurchasing cited several key factors that would influence their decision, including: the time since the recall (39%), severity of the contamination (39%), and recommendations from authorities (35%).

"Food recalls are one of the ways the food safety system works to protect consumers, whether the issue involves contamination, undeclared allergens, foreign objects or mislabeling," said Bob Carpenter, president and CEO of GS1 US. "The challenge is making recall response more precise so companies can quickly identify and remove affected products while giving consumers clearer information about what is—and is not—impacted. Traceability, supported by common standards and better data sharing across the supply chain, is essential to that effort."

Regulation aimed at strengthening recall effectiveness and improving food safety will go into effect on July 20, 2028. The U.S. Food and Drug Administration's (U.S. FDA's) Food Safety Modernization Act (FSMA) Section 204 Food Traceability Rule is designed to improve traceability for high-risk foods, such as leafy greens, eggs and others identified on the FDA's Food Traceability List, by establishing additional recordkeeping requirements to document their movement through the supply chain. The Rule requires companies subject to the regulation to maintain Key Data Elements associated with Critical Tracking Events and provide information within 24 hours if requested by the U.S. FDA.

GS1 US is helping the food industry prepare by applying GS1 Standards to support supply chain visibility, improve data sharing and enable rapid identification of affected products through ongoing education and guidance, including the FSMA Rule 204 Implementation Guideline. Additionally, as industry adoption of two-dimensional (2D) barcodes, such as QR Codes powered by GS1, advance on product packaging to support consumer engagement and Sunrise 2027 at checkout, recall management becomes a powerful use case: Richer product data, such as batch or lot information, can help trading partners and shoppers access more-precise information when safety issues occur.

For more information about GS1 Standards and food traceability to support FSMA Rule 204, visit www.gs1us.org/fsma. To view the complete survey results, visit www.gs1us.org/foodrecall.

About GS1 US

GS1 US® enables companies to power their supply chains to deliver safe, consistent, authentic and trusted experiences. Best known as a source for UPC barcodes, GS1 is a not-for-profit, global data standards organization that creates a common language for companies to identify, capture and share trusted data that links their physical and digital supply chains. Millions of businesses around the world power commerce with GS1 Standards. Learn more at www.gs1us.org.

SOURCE GS1 US

21%

more press release views with 

Request a Demo

Introducing anywear, an On-Demand Messaging Platform That Brings Professional Styling to Everyone

NEWS PROVIDED BY

anywear

Sep 01, 2026, 07:00 ET

SHARE THIS ARTICLE

New app connects consumers with professional stylists for personalized fashion advice starting at $25

NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Personal styling has long been viewed as a luxury, reserved for celebrities and high-net-worth consumers. Today, Saturday Night Live costume designer Jill Bream and stylist Alexis Teller are changing the industry with the launch of anywear, a new mobile platform that connects users directly with professional stylists through messaging for personalized, on-demand fashion advice.

Available now on the App Store and Google Play, anywear provides access to real human stylists who help with everything from event dressing and wardrobe refreshes to fit questions and in-store shopping decisions. Sessions start at $25, making expert styling more accessible than traditional personal styling services. 

Founded by New York City-based stylists Jill Bream and Alexis Teller, anywear was born from a simple observation. After decades of working in television, film, and celebrity styling, the pair found themselves constantly fielding texts from friends and colleagues seeking fashion advice. What started as an everyday occurrence quickly revealed a larger gap in the market.

"People were already coming to us every day with questions about what to wear, what to buy, and how to feel more confident in their clothes," said Alexis Teller, co-founder and CEO of anywear. "I realized that access to professional styling was still out of reach for most people. Everyone deserves to feel good in what they're wearing, and anywear makes that expertise available on-demand, at a price that's realistic for everyday life." 

Unlike fashion technology platforms built on algorithms and AI-generated recommendations, anywear is human-first by design. What anywear offers is access to experienced professionals who understand the individual, the occasion, the fit issue, and the nuances an algorithm may miss. The only role of an anywear stylist is to help consumers make better decisions and feel more confident in what they wear.

The platform offers two service options:

Signature Styling ($55): A 30-minute session designed for larger styling goals, including special events, wardrobe refreshes, workwear planning, seasonal transitions, and fit guidance. Customers receive a personalized action plan with shopping recommendations, wardrobe organization advice, or styling strategies.

Quick Fix ($25): An on-demand styling session for immediate questions, such as outfit checks, shopping decisions, closet restyling, or occasion dressing.

The launch comes as consumers increasingly seek trusted, personal recommendations in an overwhelming digital shopping landscape. Traditional styling can cost hundreds per session, while online advice often feels generic or influenced by brand partnerships. anywear closes that gap with expert, unbiased guidance that fits real schedules and budgets.

About anywear

anywear puts a professional stylist in your pocket, one text away. Founded by stylists Jill Bream and Alexis Teller, who met while working at Saturday Night Live, the platform makes professional styling accessible, affordable, and available whenever it's needed. Sessions start at $25, on the App Store and Google Play.

Media Contact

Alexis Teller

anywear

https://apps.apple.com/us/app/anywear-personal-styling/id6749256405

alexis@anywearstyling.com

917-657-8884

anywearstyling.com

SOURCE anywear

21%

more press release views with 

Request a Demo

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

NEWS PROVIDED BY

RedHill Biopharma Ltd.

Sep 01, 2026, 07:00 ET

SHARE THIS ARTICLE

Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill's commercial GI business

The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill's control, with a significantly stronger liquidity position and provides additional growth and expansion opportunities

Under the terms of the agreement, RedHill obtained the exclusive commercialization rights for an upfront payment to Ferring of $12 million plus potential future milestones and tiered royalties. 

The $12 million upfront payment is fully funded through the previously announced $18 million Talicia divestment, with RedHill securing exclusive global and U.S. commercialization rights to Ferring's Rebyota® and Clenpiq®, respectively - two synergistic, revenue-generating, FDA-approved GI drugs

Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT for prevention of recurrent C. diff infection (rCDI). FDA-approved in 2022 and Health Canada-approved in 2025, Rebyota, was granted a Breakthrough Therapy and received Orphan Drug designations and generated approximately $16.9 million in 2025 U.S. net sales

Proprietary Clenpiq, a ready-to-use (no mixing required) low-volume bowel preparation on the U.S. market, generated $20.6 million in U.S. 2025 net sales with minimal promotion

RALEIGH, N.C. and TEL AVIV, Israel, Sept. 1, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the transformational acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals ("Ferring"), as part of Ferring's ongoing strategic refocusing.

Dror Ben-Asher, RedHill's Chief Executive Officer, said: "We have executed a clear strategic sequence. We have monetized Talicia for $18 million cash upfront, plus $35 million in potential upside, used $12 million to secure commercialization rights to two established, proprietary, FDA-approved gastrointestinal drugs, that collectively generated approximately $37.5 million in U.S. net sales in 2025, and emerged with a materially larger, fully controlled commercial business and a stronger liquidity position. Rebyota and Clenpiq are expected to generate a positive cash contribution to RedHill. This, combined with RedHill's experienced and lean commercial team and proven development capabilities, creates a scalable foundation for further growth, including additional acquisition of complementary revenue-generating products." Mr. Ben-Asher added: "We thank Ferring for a smooth process to date and look forward to a successful collaboration."

Under the terms of the agreement, RedHill obtained an exclusive global commercialization license of Rebyota and an exclusive U.S. commercialization license of Clenpiq, for an upfront payment to Ferring of $12 million, plus tiered royalties on net sales and potential milestones. Ferring retains its Rebyota manufacturing facilities, and Ferring will continue to supply Rebyota through the term of the agreement.

"Rebyota is a first-in-class microbiota-based therapy for prevention of recurrent Clostridioides difficile (C. diff) infection (rCDI) in individuals 18 years of age and older following antibiotic treatment for rCDI. FDA-approved in 2022, it generated approximately $16.9 million in U.S. net sales in 2025 through its clinical profile, broad coverage and an established customer base of approximately 600 active accounts," said Rick Scruggs, RedHill's Chief Commercial Officer. "Clenpiq, a ready-to-drink low-volume bowel preparation on the U.S. market, delivered $20.6 million in net sales in 2025, with minimal promotion. Together the two assets give RedHill a significantly stronger commercial growth engine in both the U.S. and other new territories."

C. diff (CDI) infection is a distressing and life-threatening condition – in developed countries it is the most common cause of healthcare-associated (HA) diarrhea[1]. An estimated 3.6 million cases of CDI occur globally each year, including approximately half a million cases in the U.S. 30,000 Americans die every year due to CDI[2], with a global mortality rate of 1-in-10, rising to almost 1-in-3 in high-risk settings1. In the U.S., up to approximately 165,000 CDI cases result in one or more recurrences[3], indicating the need for use of prevention strategies.

Rebyota's one-time administration, which requires no fasting, bowel prep or extended treatment timeframe, has demonstrated more than a 70% success rate at preventing rCDI[4]. An aging population and accompanying increasing hospital-acquired vulnerabilities will likely increase this need. A streamlined ordering and reimbursement process is already in place for physicians, and broad and improving U.S. payer coverage means that 93% of lives have coverage including 43% with coverage after 1st recurrence[5].

Rebyota, which was granted, Breakthrough Therapy and Orphan Drug designations - with exclusivities and other patent protections that could run to 2036, provides multiple growth opportunities, including recent approval in Canada. The existing approvals also provide the potential for additional approvals in other territories.

Colonoscopy is the cornerstone of GI practice, with more than 15 million colonoscopies performed in the U.S. annually[6]. This number is rising, with follow-up needed after noninvasive screening tests that yield a positive result, an aging population, and guidelines that recommend testing at age 45 instead of age 50, contributing to an increased need for colonoscopy. Bowel preparation is not a pleasant process and is often poorly performed.

Clenpiq is a ready-to-drink low-volume bowel prep. Clenpiq is readily available to patients and has broad commercial and government payer coverage: More than 108 million lives (63%) with unrestricted (no prior approval) have commercial coverage, including 57 million (33%) with preferred position. 23m lives (41%) of Medicare Part D lives have unrestricted access to Clenpiq, including 12m (21%) lives with preferred position5.

RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.

About Rebyota®

Rebyota® (fecal microbiota, live – jslm) is a pre-packaged, single-dose 150 mL microbiota suspension for rectal administration consisting of a liquid mix of live microbes. Rebyota is administered by a healthcare professional in one visit.

Indication

Rebyota is indicated for the prevention of recurrence of Clostridioides difficile infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. difficile infection.

Limitation of Use: Rebyota is not indicated for the treatment of C. difficile infection.

Important Safety Information

You should not receive Rebyota if you have a history of a severe allergic reaction (e.g., anaphylaxis) to Rebyota or any of its components.

You should report to your doctor any infection you think you may have acquired after administration.

Rebyota may contain food allergens.

Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).

Rebyota has not been studied in patients below 18 years of age.

Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.

Please click to see the full Prescribing Information.

About CLENPIQ®

CLENPIQ® (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution is a ready-to-drink, low-volume bowel preparation used to cleanse the colon prior to colonoscopy. It combines sodium picosulfate, a stimulant laxative, with magnesium oxide and anhydrous citric acid, which form magnesium citrate, an osmotic laxative.

Indication

CLENPIQ is indicated for cleansing of the colon as a preparation for colonoscopy in adults and paediatric patients 9 years of age and older.

Important Safety Information

CLENPIQ is contraindicated in patients with severe renal impairment, gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or hypersensitivity to any of its ingredients.

Bowel preparations, including CLENPIQ, can cause serious fluid and electrolyte disturbances, which may lead to cardiac arrhythmias, seizures and renal impairment. Patients should maintain adequate hydration before, during and after use. Particular caution is required in patients with conditions or taking medications that increase the risk of fluid and electrolyte disturbances, seizures, renal impairment or cardiac arrhythmias.

CLENPIQ may cause colonic mucosal ulceration and has been associated with ischemic colitis. Caution should also be exercised in patients with severe active ulcerative colitis or an impaired gag reflex due to the risk of regurgitation or aspiration.

CLENPIQ may reduce the absorption of other orally administered medicines. The most common adverse reactions in adults include nausea, headache, hypermagnesemia, dehydration or dizziness, and abdominal pain. In paediatric patients 9 to 16 years of age, the most common adverse reactions include nausea, vomiting and abdominal pain.

Please see the full Prescribing Information and Medication Guide for CLENPIQ: www.clenpiq.com

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a privately owned, specialty biopharmaceutical group committed to building families and helping people live better lives. Ferring is a leader in reproductive medicine with a strong heritage in gastroenterology and urology, and is at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. 

About RedHill Biopharma 

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota®, for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq®. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.

More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and include, among others, statements regarding the divestment of Talicia and the potential use of the proceeds of such sale; the expected benefits of the acquisition of commercialization rights to Rebyota® and Clenpiq®, the anticipated commercial growth and cash contribution from these products, expectations regarding market share growth, anticipated payer coverage, the Company's strategic repositioning and path to operational profitability, potential use of milestone and royalty payments, and the Company's ability to successfully commercialize Rebyota® and Clenpiq®. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that the acquisition of commercialization rights for Rebyota® and Clenpiq® does not result in the planned commercial growth; the risk that opaganib is not accepted into Ebola virus disease control programs, or if accepted, that it does not demonstrate efficacy; the risk that development of RHB-204 for Crohn's disease may not be completed, or if completed may not be approved or may not achieve commercial success; the risk that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda®) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company's ability to regain and maintain compliance with Nasdaq's listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements or that they will be less than anticipated; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia; (v) the Company's ability to establish and maintain corporate collaborations; (vi) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (viii) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) the Company's ability to collect on its judgement against Kukbo; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 27, 2026. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

Company contact:

Adi Frish

Chief Corporate & Business Development Officer

RedHill Biopharma

adi@redhillbio.com 

Category: Corporate

[1] Akorful RAA, Odoom A, Awere-Duodu A, Donkor ES. The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis. Infect Dis Rep. 2025 Apr 14;17(2):31. doi: 10.3390/idr17020031. PMID: 40277958; PMCID: PMC12026862.

[2] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913. PMID: 25714160; PMCID: PMC10966662.

[3] Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023 Mar 7;23(1):132. doi: 10.1186/s12879-023-08096-0. PMID: 36882700; PMCID: PMC9990004.

[4] Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527-1538. doi:10.1007/s40265-022-01797-x.

[5] Data on file. Ferring Pharmaceuticals

[6] MarketScan Commercial Claims and Encounters and Medicare Supplemental database

Logo:  https://mmx.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

SOURCE RedHill Biopharma Ltd.

21%

more press release views with 

Request a Demo

Beyond Scalp: New study Suggests Role for Elissara® in Hair Growth

NEWS PROVIDED BY

Monteloeder, S.L.

Sep 01, 2026, 07:00 ET

SHARE THIS ARTICLE

Preclinical findings demonstrate nutricosmetic by Monteloeder may offer broad support to hair resilience

Key Takeaways

New preclinical research reveals Elissara® activity across multiple pathways associated with healthy hair growth

Elissara® shown to help preserve growth-signalling IGF-1 protein levels important for hair-follicle development under environmental stress

The findings extend Elissara®'s clinically demonstrated scalp benefits to include follicular resilience

Monteloeder will present the study results at Vitafoods Asia and SupplySide Global.

MADRID, Sept. 1, 2026 /PRNewswire/ -- Results of a new study show that Elissara®, a nutricosmetic by Monteloeder, SL, a subsidiary of SuanNutra, SA, exhibits multifactorial activity associated with healthy hair growth and hair follicle function. The four-botanical polyphenol-enriched ingredient demonstrated support of hair follicle function and hair resilience.

Hair appearance, and particularly hair loss, is a major concern affecting millions of men and women worldwide and has a substantial impact on self-esteem and social confidence.

Beyond Scalp: New study Suggests Role for Elissara® in Hair Growth

"Consumers are increasingly concerned about their hair's appearance and are seeking natural, science-backed solutions that support hair vitality," explains Mariana Ortega, Science Marketing Manager for SuanNutra. "Supplement brands are responding to the growing demand for hair health solutions. The category is evolving from multivitamins targeting hair, skin, and nails toward more advanced, targeted products. We empower supplement brands with a complete beauty-from-within toolkit, enabling them to develop next-generation solutions that complement consumers' healthy lifestyles and go beyond topical care."

"Elissara is a great example of Visible Radiance™, our branded beauty-from-within line. "This science-driven platform designed as 'plug-in' line for beauty brands," adds Ortega.

Elissara® is a proprietary combination of four herbs formulated to work together to support the scalp's environment for more vibrant and healthier looking hair. It includes standardized extracts of lemon verbena (Lippia citriodora), olive leaf (Olea europaea), Japanese pagoda tree (Styphnolobium japonicum), and rosemary (Rosmarinus officinalis).

The preparation delivers a specific fingerprint of bioactive compounds, including: verbascoside, oleuropein, hydroxytyrosol, quercetin, and rosemary-derived diterpenes (carnosol and carnosic acid). Together, these phenolic compounds provide a broad spectrum of antioxidant and anti-inflammatory activity

Getting to the root of hair growth

This three-pronged preclinical trial, published in the August 2026 issue of the journal Biomolecules involved laboratory assessments of human dermal papilla cells and scalp tissue samples exposed to environmental stressors such as pollution and UV light. Results showed that Elissara® influenced multiple biological pathways associated with healthy follicle function and the hair growth cycle. In human dermal papilla cells, Elissara® increased cell proliferation to approximately 2.5 times that of untreated controls.

Elissara® increased both collagen and signaling proteins associated with healthy hair-follicle function, including markers involved in cell proliferation, structural support and follicular signalling in human scalp explants. Elissara® was shown to help preserve growth-signalling IGF-1 protein levels important for hair-follicle development under environmental stress as well as reduce markers of oxidative damage, in scalp tissue exposed to PM2.5 pollution and UVA-induced environmental stress.

Beauty from skin to strand

"Elissara was initially developed as a natural inner beauty botanical formula to support the skin against pollution and UV exposure," informs Daniel González-Hedström, PhD, R&D Director for SuanNutra." It later exhibited scalp health benefits in a clinical study involving 66 women where daily oral supplementation significantly improved scalp moisturization and hydration, and reduced sebum levels and scalp redness. The benefits were also reflected in participants' self-assessments, with almost 79% reporting healthier-looking hair and 76% noting enhanced shine. Close to 80% of them reported that their hair felt stronger. This is what inspired us to further explore its potential in supporting hair growth."

The science of hair growth

Hair growth and follicular function are complex, shaped by a mix of genetics, hormonal changes, and inflammation, alongside lifestyle and environmental factors that can influence hair follicles. Androgens, particularly dihydrotestosterone (DHT), are known to contribute to shortening the anagen (growth) phase and shrinking hair follicles, while declining estrogen levels in women, particularly during menopause, may lead to hair thinning. Preclinical research showed that Elissara® may help support a healthier hormonal environment around the hair follicle by modulating pathways linked to DHT.

"Rather than relying on a single pathway, Elissara® combines four standardised, polyphenol-rich botanicals selected to provide complementary biological activity," says González-Hedström. "We are gradually unearthing Elissara®'s potential benefits on hair resilience. The findings of this preclinical trial provide new insights into its pathways of action and help us understand how the composition may support healthy follicular function. The next step is to investigate whether these mechanistic findings translate into measurable hair benefits in a clinical setting."

Previously marketed under the name "Zeropollution®," Elissara® is backed by two clinical trials demonstrating its positive impact on scalp condition and the hair's appearance. At a daily dose of 250 mg, it is available in various formats including tablets, capsules, or softgels.

Visit SuanNutra at Vitafoods Asia, in Bangkok, on September 2-4, booth #H5-E21 to discover how science is transformed into visible results.

About Monteloeder 

Monteloeder, SL contributes innovation and scientific rigor to the development of botanical ingredients, and by featuring proprietary patented products supported by clinical studies. Its Visible Health Platform™ reflects the company's strategic approach to translating clinical science into tangible, consumer-perceivable benefits. The platform is built upon three key pillars that address today's most relevant health areas: Visible Metabolic Health™, Visible Balance™ and Visible Radiance Monteloeder is a subsidiary of SuanNutra, which boasts a rich heritage of more than 125 years of combined experience in the European, US and Asian nutraceutical sector.

Company contact 

Monteloeder, S.L., a subsidiary of SuanNutra

Mariana Ortega

Science Marketing Manager

E-mail: info@monteloeder.com

Website: www.suannutra.com

Press Contact

NutriPR

Liat Simha 

Tel: +972-9-9742893

E-mail: liat@nutripr.com 

Website: www.nutripr.com

SOURCE Monteloeder, S.L.

21%

more press release views with 

Request a Demo

Innovative Beverage Concepts Marks 30 Years of Premium Beverage Innovation Serving the Global Foodservice Industry

NEWS PROVIDED BY

INNOVATIVE BEVERAGE CONCEPTS INC.

Sep 01, 2026, 07:00 ET

SHARE THIS ARTICLE

Company celebrates three decades of innovation as continued sales growth, expanding distribution, new customer relationships, and a robust product pipeline position IBC for its next chapter of growth

IRVINE, Calif., Sept. 1, 2026 /PRNewswire/ -- Innovative Beverage Concepts (IBC), the company behind the trusted MOCAFE®, TEAOLOGY®, and MODERN OATS® brands, today celebrates its 30th anniversary, marking three decades of innovation, customer partnership, and leadership in premium specialty beverage solutions for the global foodservice industry.

IBC brands include: MOCAFE™, TEAOLOGY®, and MODERN OATS®

As it enters its fourth decade, IBC continues to build on that foundation with strong and sustained growth. The company has grown 31% since 2021, including 17.1% year-over-year growth, while continuing to expand its customer base, distribution network, product portfolio, and reach across foodservice and emerging channels.

Professional Coffee Bar Products Since 1996

Founded in 1996, Innovative Beverage Concepts has built a reputation as a trusted developer and manufacturer of premium beverage and foodservice products that help operators deliver exceptional café-quality experiences while improving operational efficiency and profitability. Today, IBC's brands are served in cafés, coffeehouses, restaurants, hotels, universities, convenience retailers, and institutional foodservice operations throughout North America and international markets.

IBC continues to broaden its market reach through an expanding base of customers and distribution partners, making its products increasingly accessible to foodservice operators across a wide range of channels. The company's established brands, growing distribution footprint, and ability to develop products for both longstanding and emerging beverage categories have created a strong platform for continued expansion.

For 30 years, the company has remained focused on a single mission: developing innovative, high-quality products that enable foodservice operators to serve premium beverages with consistency, speed, and confidence. By anticipating evolving consumer preferences and introducing new beverage concepts ahead of emerging trends, IBC has established itself as a valued innovation partner to customers and distributors across the specialty beverage industry.

Its flagship MOCAFE™ brand has earned the trust of coffee professionals for premium frappes, mochas, specialty lattes, chai, matcha, hot chocolate, smoothies, refreshers, and other café-inspired beverages that deliver exceptional taste and operational simplicity. Complementing MOCAFE, TEAOLOGY® offers premium tea-based beverage solutions, while MODERN OATS® extends the company's commitment to convenient, high-quality foodservice offerings that meet today's evolving consumer demands.

Throughout its history, Innovative Beverage Concepts has successfully navigated multiple generations of beverage innovation—from the rise of blended coffee beverages and specialty espresso drinks to the continued growth of chai, matcha, smoothies, premium hot chocolate, and today's rapidly expanding café-inspired beverage categories. This ability to identify emerging consumer trends and transform them into successful commercial products has enabled IBC to remain a trusted supplier and long-term partner for foodservice operators for more than three decades.

"When we founded Innovative Beverage Concepts 30 years ago, our vision was straightforward: create exceptional products that coffee professionals would be proud to serve while helping operators build stronger, more profitable businesses," said Richard Principale, Co-Founder and Chief Executive Officer of Innovative Beverage Concepts. "We're deeply grateful for the trust our customers, distributor partners, suppliers, and employees have placed in us over the past three decades. Those relationships have been the foundation of our success, and they continue to inspire us to innovate, expand, and develop new products that help our customers succeed every day."

IBC's continued growth reflects both the strength of its established product portfolio and its ongoing expansion into new customers, distribution relationships, and market opportunities. With demand for premium café-style beverages continuing to expand across traditional coffeehouses as well as restaurants, hotels, convenience, education, hospitality, and other foodservice channels, the company sees significant opportunity to bring its brands and products to an even broader range of operators.

Product innovation remains a central component of the company's growth strategy. IBC continues to invest in research, formulation, and commercialization of new specialty beverage solutions, with a robust pipeline of new products planned for introduction over the next year. These innovations are being developed to address emerging consumer tastes, provide operators with differentiated menu opportunities, and make premium beverage preparation easier and more profitable.

IBC is also increasing its investment in programs designed to strengthen customer engagement and support long-term growth. As part of that strategy, the company plans to introduce MoPerks™, a new customer loyalty and engagement program providing participating customers with exclusive promotions, rewards, educational resources, and business-building opportunities. MoPerks represents one component of IBC's broader commitment to strengthening relationships with cafés, restaurants, distributors, and foodservice operators while creating additional value for customers who grow their businesses with IBC brands.

"This milestone reflects the dedication of our employees, the loyalty of our customers, and the strength of the partnerships we've built over the past 30 years," said Peter Scialdone, Co-Founder and Vice President of Innovative Beverage Concepts. "The specialty beverage industry continues to present tremendous opportunities for operators seeking differentiated, premium beverage solutions. With our expanding customer and distribution base and a strong pipeline of new products ahead, we're excited about the opportunities in front of us and remain committed to delivering the innovation, service, and value that help our customers grow."

As Innovative Beverage Concepts enters its fourth decade, the company is building on the strength of three established brands, an increasingly broad market presence, continued business growth, an expanding distribution network, and a deep pipeline of new product innovation. IBC remains committed to the values that have defined its success for 30 years: quality without compromise, trusted partnerships, continuous innovation, and an unwavering commitment to customer success.

About Innovative Beverage Concepts

Founded in 1996 and headquartered in Irvine, California, Innovative Beverage Concepts is a leading developer and manufacturer of premium specialty beverage and foodservice solutions. Through its flagship brands—MOCAFE®, TEAOLOGY®, and MODERN OATS®—the company offers a comprehensive portfolio of professional beverage products, including frappes, mochas, specialty lattes, chai, matcha, hot chocolate, smoothies, refreshers, specialty beverage mixes, and premium oatmeal solutions.

Trusted by cafés, coffeehouses, restaurants, hotels, universities, distributors, convenience retailers, and foodservice operators across North America and international markets, Innovative Beverage Concepts has spent 30 years helping customers deliver premium café-quality experiences while improving operational efficiency and beverage profitability. With continued business growth, expanding distribution, ongoing customer acquisition, and a robust pipeline of new products, IBC is positioned to continue expanding its role in the global specialty beverage industry.

Media Contact:

Jim Wendt

Director of Sales & Marketing

Innovative Beverage Concepts

(657) 521-1073

SOURCE INNOVATIVE BEVERAGE CONCEPTS INC.

21%

more press release views with 

Request a Demo

See all essential data on a sleek, high-resolution color display with the intuitive GMI 40 from Garmin

NEWS PROVIDED BY

Garmin International, Inc.

Sep 01, 2026, 07:01 ET

SHARE THIS ARTICLE

Modern multipurpose marine instrument seamlessly integrates with other Garmin onboard electronics to keep mariners informed in real time

OLATHE, Kan., Sept. 1, 2026 /PRNewswire/ -- Garmin (NYSE: GRMN), the world's largest1 and most innovative marine electronics manufacturer, today unveiled the GMI™ 40 multipurpose marine instrument that displays live boating insights in an easy-to-read format. Boasting a modern, streamlined design that complements Garmin GPSMAP® chartplotters, the device has an intuitive touchscreen interface with edge-to-edge glass on a 4.3-inch, high-resolution, color LCD display. The touchscreen optimizes space for a clear, uninterrupted view of instrumentation data, keeping sailors, cruisers and coastal anglers informed throughout the trip. 

Modern multipurpose marine instrument seamlessly integrates with other Garmin onboard electronics to keep mariners informed in real time.

"Whether sailing, fishing the coast or cruising for the weekend, you need a compact instrument that's simple to operate and fits cleanly at the helm. Our new GMI 40 delivers that and more with a modern display that networks seamlessly across Garmin's marine products, putting the real-time data you rely on in one place." — Susan Lyman, Garmin Vice President of Global Consumer Sales & Marketing

Smooth integration

The cutting-edge GMI 40 integrates with compatible devices on board via the NMEA 2000® network and the Garmin BlueNet™ network. The powerful marine instrument also has wireless connectivity with gWind™ wireless sensors, marine remote controls and Garmin quatix® marine smartwatches, allowing for easy sharing of data.

Mariners can also keep their GMI 40 software up-to-date via the free, all-in-one ActiveCaptain® app on their compatible smartphone. When upgrading from the GMI 20, users can purchase an adapter plate to easily install the GMI 40 into the existing cutout in the dash.

Upgraded data options

Mariners can purchase the GMI 40 on its own, or as part of an exciting bundle to receive enhanced wind and water information. Bundle options include a gWind™ wired or wireless transducer, which provides a three-bladed anemometer for more accurate wind speed and a twin-fin design for a more stable True Wind Angle (TWA). Boaters can also opt to receive more detailed data below the surface by including a DST820 thru-hull smart transducer or GDT™ 43 transducer (depth and temperature) and GST™ 43 (speed/temperature) transducer with their bundle.

The GMI 40 marine instrument is available now with a suggested retail price of $599.99. The GMI 40 bundles range from $1,099.99 to $1,899.99. To learn more, visit garmin.com/marine.

Engineered on the inside for life on the outside, Garmin products have revolutionized life for anglers, sailors, mariners and boat enthusiasts everywhere. Committed to developing the most innovative, highest quality, and easiest to use marine electronics the industry has ever known, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. For the 11th consecutive year, Garmin was named the Manufacturer of the Year by the National Marine Electronics Association (NMEA). Visit the Garmin Newsroom, email our media team, connect with @garminmarine on social, or follow our blog.  

1Based on 2025 sales.

About Garmin: Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan, and the United Kingdom. Garmin, GPSMAP NMEA 2000, quatix and ActiveCaptain are registered trademarks, and GMI, BlueNet, gWind, GDT, and GST are trademarks of Garmin Ltd., or its subsidiaries.

All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.

Notice on Forward-Looking Statements:

This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 27, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). Copies of such Form 10-K are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

MEDIA CONTACTS:

Mike Cummings and Carly Hysell

913-397-8200

media.relations@garmin.com

SOURCE Garmin International, Inc.

21%

more press release views with 

Request a Demo

Bond Fluidaire and West Michigan Rubber Change Name to Exotic Automation

NEWS PROVIDED BY

Exotic Automation

Sep 01, 2026, 07:00 ET

SHARE THIS ARTICLE

Bond Fluidaire & West Michigan Rubber have been a part of the Exotic Automation family since 2022 & 2025, respectively.

NEW HUDSON, Mich., Sept. 1, 2026 /PRNewswire/ -- Exotic Automation, a premier Parker Hannifin distributor, announced today they have completed the rebrand of their subsidiaries, Bond Fluidaire & West Michigan Rubber, to Exotic Automation.

Bond Fluidaire was acquired by Exotic in 2022 and has since undergone several key expansions, including an expanded product portfolio, geographic presence and service levels. A new location was opened in Kalamazoo, offering customers custom hose assemblies made on the spot as well as in-stock pneumatic and hydraulic inventory. The company's two Grand Rapids store locations were both remodeled, offering a wider selection of inventory and product demos. Bond Fluidaire also became a supplier of several new key suppliers, including SKF, DESTACO, Enerpac, Ace Controls and Perma.

West Michigan Rubber was acquired by Exotic in 2025 and underwent a major store remodeling which brought more in-stock products and fluid power capabilities to the Muskegon area. Since the acquisition, the company has significantly increased customer service levels and gained access to Exotic's pneumatic, hydraulic, compressed air and engineered systems lines.

"The investments made to Bond and West Michigan Rubber have been significant and both companies are stronger than when we acquired them." Steve Orlando, President said. "The growth experienced over the past few years is just the beginning and gaining the Exotic brand name will allow us to evolve more quickly and surpass expectations for customers."

All future Bond Fluidaire & West Michigan Rubber correspondences will come from Exotic Automation. Contact information will remain the same. Please visit www.exoticautomation.com for more information. 

About Exotic Automation & Supply: Exotic Automation & Supply was founded in 1963 and has grown to become a leading provider of motion & control solutions. The company has retail store locations throughout Michigan & Indiana and offers a comprehensive selection of solutions including custom hoses and fittings, pneumatic and hydraulic components, filtration, lubrication equipment, engineered power units, compressed air equipment & more.

SOURCE Exotic Automation

21%

more press release views with 

Request a Demo

Montana Renewables Announces Innovative, Capital-Efficient Expansion to 200 Million Gallons of Sustainable Aviation Fuel

NEWS PROVIDED BY

Calumet, Inc.

Sep 01, 2026, 07:00 ET

SHARE THIS ARTICLE

SAF production capacity expected to reach approximately 200 million gallon annual run rate by year-end 2028, with total renewable product sales expanded 40% to 17,000 barrels per day

Remaining project capital for this expansion reduced to $137 million from the $1.2 billion contemplated in the original Phase 2 plan, driven by the repurposing of proven equipment from the adjacent Calumet Montana Refining asphalt facility through a series of quick-payback steps

No third-party equity requirement provides simple capital structure and eliminates dilution, positioning MRL for future strategic opportunities; expansion is expected to be funded with Montana Renewables earnings alongside a final $34 million draw under a DOE loan

Calumet Montana Refining will continue to produce retail asphalt and provide shared site cost efficiencies across both businesses, preserving all Great Falls jobs

INDIANAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Calumet, Inc. (NASDAQ: CLMT) ("Calumet," "we," "our" or "us") announced today a new flight plan for its MaxSAF® expansion at Montana Renewables, LLC ("Montana Renewables" or "MRL"), an unrestricted subsidiary of Calumet. By repurposing proven, installed refining equipment from the adjacent Calumet Montana Refining ("CMR") facility, Montana Renewables expects to reach approximately 200 million gallons of annual Sustainable Aviation Fuel ("SAF") production and 17,000 barrels per day of total product sales by year-end 2028. The total remaining project capital spend for this expansion is $137 million, compared to the $1.2 billion megaproject contemplated in the original loan issued by the U.S. Department of Energy ("DOE") through its Office of Energy Dominance Financing ("EDF").

Reflecting the dramatically lower capital requirement, Montana Renewables and EDF have amended the Loan Guarantee Agreement ("LGA") originally executed in January 2025. Phase 2 DOE funding is reduced from up to $658 million to a single, final draw of $34 million, with the balance of the expansion self-funded from MRL earnings. The original agreement required the project's full equity to be committed before Phase 2 construction. The amended structure requires no third-party equity, thereby eliminating dilution and preserving a simple capital structure for future strategic opportunities while accelerating the benefits of increased throughput, SAF, improved yields, and reduced unit costs.

The centerpiece of the revised plan is the redeployment of selected CMR assets — a hydrotreater, hydrogen plant, and naphtha splitter — to Montana Renewables under a long-term lease. The tied-in hydrotreater creates a proprietary dual reactor system that runs in a "polishing" service rather than the industry-standard "cracking" service, delivering competitively advantaged SAF yields while lowering by-product production and reducing yield loss. Several additional modular components, including a third renewable fuels reactor currently offsite, provide the ability to expand capacity beyond 200 million gallons over time. 

Rather than a single large construction project, the new expansion is structured as six small, controllable, quick-payback projects, each designed to increase returns and reduce construction risk. Following constraint removal completed at the Spring 2026 turnaround, Montana Renewables is currently producing at a run-rate of 60 million gallons of SAF per year; expects to exceed an 80 million gallon run-rate by year-end 2026; surpass 120 million gallons by Spring 2027; and reach approximately 200 million gallons by year-end 2028. The program also captures approximately 20 million gallons per year of renewable propane and butane — previously burned as fuel gas — as saleable product, improves renewable naphtha yields, and reduces unit operating costs through scale and lower water usage.

The reconfiguration represents the next evolution of more than a decade of modernization at the Great Falls site under Calumet's ownership. The turnaround to complete the tie-in is scheduled for the fourth quarter of 2026 — timing that allows CMR to capture approximately $50 million of EBITDA at currently elevated global refining margins before the transition. CMR will remain in service, continuing to produce high-quality retail asphalt, retaining all employees, and providing shared cost efficiencies across the full site.

"Our amended agreement with the DOE facilitates innovative technology and domestic energy security at a fraction of the original cost," said Todd Borgmann, CEO of Calumet. "EDF's willingness to right-size the LGA reflects its ongoing support for Montana's largest agricultural investment. We look forward to our continued collaboration with the DOE on the success of this project."

"We've worked hard to unleash the ingenuity of our engineering and operational teams, and they developed a project that captures approximately 70% of the originally expected benefit while spending only 15% of the originally expected Phase 2 capital," Borgmann continued. "The DOE has kept our nation's energy independence goals at the forefront while demonstrating tremendous flexibility in thoughtfully working with us to adjust the loan. MRL was honored to be the first project to receive the support of the current Administration, and we thank the entire DOE team for its continued commitment to this key component of America's energy infrastructure. With the DOE's support, Montana Renewables continues to strengthen its position as one of the world's largest SAF producers while supporting regional agriculture, the Montana business community, our employees, and our shareholders."

The expansion increases MRL's total feedstock consumption to approximately 2 billion pounds of ranch- and farm-originated feedstocks, converted into American-made renewable jet fuel, diesel, and gasoline annually, while continuing to grow Montana's wage and tax base with highly skilled technical employment in a rural community.

Amended Loan Guarantee Structure

The DOE loan remains structured in two tranches. The first tranche of $782 million was funded in February 2025 and used to recapitalize MRL, including an additional $150 million equity investment by Calumet with cash on hand. Under the amended agreement, the remaining loan availability is reduced to a single, final draw of $34 million — down significantly from the previous additional draw of up to $658 million, which MRL expects to receive shortly, subject to the satisfaction of certain commercial, technical, and legal conditions precedent.

During construction, retained earnings from MRL are expected to supplement DOE funds to maintain debt at less than 55% of eligible spending. The loan retains its 15-year tenor and an annual interest rate of the U.S. Treasury rate plus 3/8%, with servicing of principal and interest deferred until MaxSAF® is commissioned. The March 2029 first servicing date and December 2039 maturity remain unchanged. The amended LGA will be filed with the Securities and Exchange Commission ("SEC"), and investors should refer to the filed agreement for complete terms.

About Montana Renewables

Montana Renewables (MRL) is a leading renewable fuel company located in Great Falls, Montana. We produce Sustainable Aviation Fuel (SAF), Renewable Diesel, Renewable Hydrogen, and Renewable Naphtha. As one of only three SAF producers running at commercial scale in North America, we meet the increasing demand for sustainable jet fuels. As a Great Falls business leader, MRL offers high-paying jobs and career opportunities while supporting the local economy and contributing to the community's overall well-being.  Pacific Northwest farm and ranch operations ultimately provide MRL with sustainable, renewable, low-carbon feedstocks and agricultural byproducts including tallow, distillers corn oil, canola oil, used cooking oil and camelina oil.  These are converted to renewable transportation fuels which have lower emissions compared to conventional fossil fuels.  MRL is an unrestricted subsidiary of Calumet, Inc.

About Calumet

Calumet, Inc. (NASDAQ: CLMT) manufactures, formulates, and markets a diversified slate of specialty branded products and renewable fuels to customers across a broad range of consumer-facing and industrial markets. Calumet is headquartered in Indianapolis, Indiana and operates twelve facilities throughout North America.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements and information in this press release may constitute "forward-looking statements." The words "will," "may," "intend," "believe," "expect," "outlook," "forecast," "anticipate," "estimate," "continue," "plan," "should," "could," "would," "project" or other similar expressions are intended to identify forward-looking statements, which are generally not historical in nature. The statements discussed in this press release that are not purely historical data are forward-looking statements, including, but not limited to, the statements regarding (i) our expectations regarding the timing and funding of the final $34 million draw under the DOE's guaranteed loan facility (the "DOE Facility"), the satisfaction of the commercial, technical and legal conditions precedent to such draw and the intended use under the DOE facility, (ii) our expectations regarding the MaxSAF® expansion, including the redeployment and long-term lease of certain CMR assets, the design, tie-in and performance of the resulting dual reactor system, the timing and scope of the fourth quarter 2026 turnaround, the completion of each project stage on the anticipated timeline and budget, and our ability to reach approximately 200 million gallons of annual SAF production and 17,000 barrels per day of total product sales by year-end 2028, (iii) our expectations regarding total remaining project capital of approximately $137 million and our ability to fund the balance of the expansion from MRL earnings without third-party equity, (iv) our expectations regarding continued CMR asphalt operations, shared site cost efficiencies and CMR's ability to capture approximately $50 million of EBITDA prior to the transition, (v) our expectation regarding our business outlook and cash flows, including with respect to the Montana Renewables business, and (vi) our ability to meet our financial commitments, debt service obligations, debt instrument covenants, contingencies and anticipated capital expenditures. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Our forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause our actual results to differ materially from our historical experience and our present expectations or projections. Known material factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: the overall demand for renewable fuels, including SAF and renewable diesel; our ability to produce renewable fuel products that meet our customers' unique and precise specifications; our ability to complete the redeployment, lease and tie-in of the CMR hydrotreater, hydrogen plant and naphtha splitter on the anticipated timeline and budget; the risk that repurposed or relocated equipment does not perform as designed or requires additional capital, maintenance or downtime; the risk that turnaround activities take longer, cost more or achieve less than anticipated; our ability to satisfy the conditions precedent to the final DOE draw and to comply with the covenants and other terms of the amended LGA; changes in DOE policy, priorities, funding or administration affecting the loan guarantee; changes in federal, state and international policies, mandates, tax credits and incentives applicable to renewable fuels; the marketing of alternative and competing products; the impact of fluctuations and rapid increases or decreases in renewable fuel margins, including the resulting impact on our liquidity; our ability to comply with financial covenants contained in our debt instruments; labor relations; our access to capital to fund expansions, acquisitions and our working capital needs and our ability to obtain debt or equity financing on satisfactory terms; environmental liabilities or events that are not covered by an indemnity, insurance or existing reserves; maintenance of our credit ratings and ability to receive open credit lines from our suppliers; demand for various feedstocks and resulting changes in pricing conditions; fluctuations in refinery capacity; our ability to access sufficient feedstocks; the effects of competition; continued creditworthiness of, and performance by, counterparties; the impact of current and future laws, rulings and governmental regulations; shortages or cost increases of power supplies, natural gas, materials or labor; weather interference with business operations; administration changes in the federal government and potential legislative enactments and administrative actions; our ability to access the debt and equity markets; accidents or other unscheduled shutdowns; and general economic, market, business or political conditions, including inflationary pressures, instability in financial institutions, general economic slowdown or a recession, political tensions, conflicts and war (such as the ongoing conflicts in Ukraine and the Middle East and their regional and global ramifications).

For additional information regarding factors that could cause our actual results to differ from our projected results, please see our filings with the SEC, including the risk factors and other cautionary statements in our latest Annual Report on Form 10-K and our other filings with the SEC.

We caution that these statements are not guarantees of future performance and you should not rely unduly on them, as they involve risks, uncertainties, and assumptions that we cannot predict. In addition, we have based many of these forward-looking statements on assumptions about future events that may prove to be inaccurate. While our management considers these assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. Accordingly, our actual results may differ materially from the future performance that we have expressed or forecast in our forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by applicable law. Certain public statements made by us and our representatives on the date hereof may also contain forward-looking statements, which are qualified in their entirety by the cautionary statements contained above.

Non-GAAP Financial Measure

This press release includes a forward-looking estimate of EBITDA for CMR prior to the completion of the MaxSAF® expansion, which is a non-GAAP financial measure. We define EBITDA for any period as net income (loss) plus interest expense (including amortization of debt issuance costs), income taxes and depreciation and amortization. This non-GAAP measure is used as a supplemental financial measure by our management and by external users of our financial statements such as investors, commercial banks, research analysts and others.

We are unable to provide a reconciliation of this forward-looking non-GAAP measure to its most directly comparable measure presented in accordance with generally accepted accounting principles ("GAAP") without unreasonable efforts because the items required for such a reconciliation, including net income and income tax expense, cannot be reasonably predicted. EBITDA should not be considered in isolation or as a substitute for measures prepared in accordance with GAAP.

SOURCE Calumet, Inc.

21%

more press release views with 

Request a Demo